<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">SUFENTANIL CITRATE</span><br/>(soo-fen'ta-nil)<br/><span class="topboxtradename">Sufenta<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">narcotic (opiate) agonist analgesic</span>; <span class="classification">general anesthetic</span><br/><b>Prototype: </b>Morphine<br/><b>Pregnancy Category: </b>C<br/><b>Controlled Substance: </b>Schedule II<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mcg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic opioid related to fentanyl with similar pharmacologic actions, but about 7 times more potent. Onset of action and
         recovery from anesthesia occur more rapidly with sufentanil than with fentanyl. In common with other opiate agonists, sufentanil
         can cause respiratory depression and suppression of cough reflex.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective agent for analgesia as a supplement or a primary anesthesia.</p>
<h1><a name="uses">Uses</a></h1>
<p>Analgesic supplement in maintenance of balanced general anesthesia and also as a primary anesthetic.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Pregnancy (category C), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pulmonary disease, reduced respiratory reserve; impaired liver or kidney function.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Adjunct to General Anesthesia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 18 mcg/kg, depending on duration of surgery, may give additional doses of 1025 mcg if needed<br/><br/><span class="indicationtitle">As Primary Anesthetic</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 130 mcg/kg administered with 100% oxygen and a muscle relaxant, may give additional doses of 1025 mcg if needed<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> <i> 1025 mcg/kg administered with 100% oxygen and a muscle relaxant, may give additional doses of 2550 mcg up
               to 12 mcg/kg/dose if needed<br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Administer only by qualified personnel, specifically trained in the use of IV anesthesia and in the management of respiratory
                     depression.
                  </li>
<li>Have available a narcotic antagonist (e.g., naloxone) to reverse respiratory depression.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Examine solution for particulate matter and discoloration (solution should be clear) before administration. Give undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give a bolus dose over 35 sec.  <span class="methodtype">Epidural:</span> Give by slow injection and closely monitor respirations after each injection.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> <b>Diazepam,</b> <b>lorazepam,</b> <b>phenobarbital,</b> <b>phenytoin,</b> <b>sodium bicarbonate.</b> <span class="incompattype">Y-site:</span> <b>Lorazepam,</b> <b>phenytoin,</b> <b>thiopental.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F) unless otherwise directed; protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Bradycardia, tachycardia, hypotension, hypertension, arrhythmias. <span class="typehead">GI:</span> Nausea, vomiting, constipation. <span class="typehead">Respiratory:</span> Bronchospasm, <span class="speceff-both">respiratory depression, apnea</span>. <span class="typehead">Body as a Whole:</span> <span class="speceff-common">Skeletal muscle rigidity (especially of trunk),</span> chills, <span class="speceff-common">itching,</span> spasms of sphincter of Oddi, urinary retention. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">beta-adrenergic antagonists</span> increase incidence of bradycardia; <b>alcohol</b> and other <span class="classification">cns depressants</span> such as <span class="classification">barbiturates</span>, <span class="classification">tranquilizers</span>, <span class="classification">opiates</span> and <span class="classification">inhalation general anesthetics</span> add to CNS depression; <b>cimetidine</b> increases risk of respiratory depression. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 1.53 min. <span class="typehead">Duration:</span> 40 min. <span class="typehead">Distribution:</span> Crosses bloodbrain barrier. <span class="typehead">Metabolism:</span> Metabolized in liver and small intestine. <span class="typehead">Elimination:</span> Excreted in urine and feces. <span class="typehead">Half-Life:</span> 23 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor vital signs. Observe for skeletal muscle rigidity, especially of chest wall, and respiratory depression, particularly
            in older adults, and in patients who are obese, debilitated, or who have received high doses.
         </li>
<li>Bear in mind that if naloxone is given to reverse respiratory depression, the duration of sufentanil-induced respiratory depression
            may exceed the duration of naloxone.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Avoid activities which require mental alertness for at least 24 h after receiving this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>